Clinical Trials Browser

Active not recruiting × INDUSTRY × Solid Tumor × Clear all

NCT06487858 2026-03-18

A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT03207672 2026-03-03

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06631079 2026-01-08

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06220318 2025-11-28

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05119907 2025-11-17

Study of Sacituzumab Govitecan in Patients With Solid Tumor

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05627063 2025-10-20

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05642780 2025-10-14

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05718557 2025-08-03

Study of PYX-106 in Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05379946 2025-04-08

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Phase 1/2 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05580991 2025-02-13

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT05037149 2024-03-18

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT03865082 2022-02-17

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Phase 2 Active not recruiting

Other solid neoplasm

Solid Tumor